Psoriatic arthritis

Blumberg BS , Bunim JJ , Calkins E , Pirani CL , Zvaifler NJ. ARA nomenclature and classification of arthritis and rheumatism (tentative). Arthritis Rheum 1964; 7: 93–7

Wright V. A unifying concept for the spondyloarthropathies. Clin Orthop Rel Res 1979; 143: 8–14

McGonagle D , Gibbon W , Emery P. Classification of inflammatory arthritis by enthesitis. Lancet 1998; 352: 1137–40

Bulbul R , Williams WV , Schumacher HR Jr . Psoriatic arthritis. Diverse and sometimes highly destructive. Postgrad Med 1910; 97: 97–9

Espinoza LR , Cuellar ML , Silveira LH. Psoriatic arthritis. Curr Opin Rheumatol 1992; 4: 470–8

Oriente P , Biondi-Oriente C , Scarpa R. Psoriatic arthritis. Clinical manifestations. Bailière's Clin Rheumatol 1994; 8: 277–94

Jones SM , Armas JB , Cohen MG , Lovell CR , Evison G , McHugh NJ. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994; 33: 834–9

Wright V. Psoriatic arthritis. In: Kelley WN , Harris ED , Ruddy S , Sledge CB , eds. Textbook of Rheumatology. 3rd edn. Philadelphia: WB Saunders, 1989: 1021–31

Gladman DD , Farewell VT , Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995; 22: 675–9

Gladman DD , Farewell VT , Wong K , Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998; 41: 1103–10

Helliwell PS , Wright V , Klippel JH , Dieppe P. eds. Rheumatology, 2nd edn. London: Mosby, 1998: 6.21

Gladman DD , Farewell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum 1995; 38: 845–50

Gladman DD , Farewell VT , Kopciuk KA , Cook RJ. HLA markers and progression in psoriatic arthritis. J Rheumatol 1998; 25: 730–3

Pitzalis C. Skin and joint disease in psoriatic arthritis: what is the link? Br J Rheumatol 1998; 37: 480–3

Punzi L , Bertazzolo N , Pianon M , Rizzi E , Rossini P , Gambari P. Value of synovial fluid interleukin-1 beta determination in predicting the outcome of psoriatic monoarthritis. Ann Rheum Dis 1996; 55: 642–4

Moll JM , Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55–78

Salvarani C , Olivieri I , Cantini F , Macchioni L , Boiardi L. Psoriatic arthritis. Curr Opin Rheumatol 1998; 10: 299–305

Marsal S , Armadans-Gil L , Martinez M , Gallardo D , Ribera A , Lience E. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford) 1999; 38: 332–7

Salvarani C , Cantini F , Olivieri I Isolated peripheral enthesitis and/or dactylitis: a subset of psoriatic arthritis. J Rheumatol 1997; 24: 1106–10

Battistone MJ , Manaster BJ , Reda DJ , Clegg DO. The prevalence of sacroilitis in psoriatic arthritis; new perspectives from a large, multicenter cohort. A Department of Veterans Affairs Cooperative Study. Skeletal Radiol 1999; 28: 196–201

Eastmond CJ. Psoriatic arthritis. Genetics and HLA antigens. Bailière's Clin Rheumatol 1994; 8: 263–76

Barker JN. The immunopathology of psoriasis. Bailière's Clin Rheumatol 1994; 8: 429–38

Pitzalis C , Cauli A , Pipitone N Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum 1996; 39: 137–45

Dougados M , vam der Linden S , Leirisalo-Repo M Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38: 618–27

Rahman P , Gladman DD , Cook RJ , Zhou Y , Young G. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998; 25: 1957–61

Spadaro A , Riccieri V , Sili-Scavalli A , Sensi F , Taccari E , Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995; 13: 589–93

Mahrle G , Schulze HJ , Farber L , Weidinger G , Steigleder GK. Lowdose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78–88

Korstanje MJ , Bilo HJ , Stoof TJ. Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy. Br J Dermatol 1992; 127: 501–4

Yocum DE. Combination therapy with cyclosporin in rheumatoid arthritis. Br J Rheumatol 1996; 35(suppl 2):19–23

Keystone EC. The role of tumor necrosis factor antagonism in clinical practice. J Rheumatol 1999; 26(suppl 57):22–8

Popovic M , Stefanovic D , Pejnovic N Comparative study of the clinical efficacy of four DMARDs (leflunomide, methotrexate, cyclosporine, and levamisole) in patients with rheumatoid arthritis. Transplant Proc 1998; 30: 4135–6

Spuls PI , Witkamp L , Bossuyt PM , Bos JD. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997; 137: 943–9

van de Kerkhof PC. An update on vitamin D3 analogues in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 1998; 11: 2–10